Reimagining Biotech with Jake Becraft of Strand Therapeutics — Tim’s Founder Kitchen
Tim Ferriss · 2:06:18 · 1 months ago
Strand Therapeutics aims to move beyond incremental drug development by building "platform therapeutics"—programmable RNA medicines that can be customized for various diseases. To scale this, the company is actively pushing for regulatory reform to fix the slow, expensive, and risk-averse environment that currently hinders American biotech innovation.
- Programmable medicines — Strand designs RNA therapies that teach certain cells to produce the correct proteins, allowing the body to naturally fix or remove diseases at their source .
- Regulatory barriers — Current U.S. rules for starting a first-in-human trial are overly burdensome, forcing companies to spend millions on documents instead of breakthrough research, effectively incentivizing only minor, 10% improvements over true innovation .
- The platform model — Instead of treating each drug as a one-off project, the company is building a reusable "delivery" infrastructure—much like SpaceX developed reusable rockets—to apply therapeutic payloads to various organs beyond the liver .
- Immune education — Through the "abscopal effect," the team has shown that injecting their medicine into a single accessible tumor can train the immune system to recognize and destroy hidden, metastatic cancer throughout the body .
- Policy impact — By publishing an op-ed in the Washington Post, the company successfully elevated the conversation about U.S. clinical trial competitiveness, resulting in the issue being included in presidential legislative objectives within two months .
- Shorting the launch — The current market encourages biotech companies to sell assets before they reach the commercial market, creating a structural weakness where few companies retain the expertise to actually launch and deliver drugs to patients .